Gilead Sciences (NASDAQ:GILD) Price Target Cut to $167.00 by Analysts at Rothschild & Co Redburn

Gilead Sciences (NASDAQ:GILD) had its price target decreased by research analysts at Rothschild & Co Redburn from $170.00 to $167.00 in a research note issued to investors on Monday,MarketScreener reports. Rothschild & Co Redburn’s price objective would indicate a potential upside of 24.48% from the stock’s previous close.

Several other research analysts also recently weighed in on the company. Scotiabank boosted their target price on Gilead Sciences from $140.00 to $177.00 and gave the stock a “sector outperform” rating in a research note on Wednesday, February 11th. Argus raised their price target on Gilead Sciences from $135.00 to $165.00 and gave the stock a “buy” rating in a report on Thursday, February 19th. Truist Financial restated a “buy” rating and set a $157.00 price target (up from $155.00) on shares of Gilead Sciences in a research note on Friday. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Gilead Sciences in a research report on Thursday, January 22nd. Finally, Jefferies Financial Group began coverage on shares of Gilead Sciences in a research note on Tuesday, March 10th. They issued a “buy” rating and a $180.00 target price for the company. Twenty-four research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $157.04.

Gilead Sciences Price Performance

Shares of GILD stock opened at $134.15 on Monday. Gilead Sciences has a twelve month low of $96.18 and a twelve month high of $157.29. The company has a current ratio of 1.97, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89. The stock has a fifty day simple moving average of $139.59 and a two-hundred day simple moving average of $132.87. The stock has a market capitalization of $166.51 billion, a price-to-earnings ratio of 18.25 and a beta of 0.31.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, beating the consensus estimate of $1.91 by $0.12. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The firm had revenue of $6.96 billion during the quarter, compared to the consensus estimate of $6.91 billion. During the same period in the previous year, the company posted $1.81 earnings per share. The firm’s quarterly revenue was up 4.4% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. On average, analysts predict that Gilead Sciences will post -0.85 EPS for the current fiscal year.

Insider Activity at Gilead Sciences

In other news, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction on Tuesday, April 28th. The stock was sold at an average price of $129.16, for a total transaction of $1,291,600.00. Following the transaction, the chief executive officer owned 632,567 shares in the company, valued at $81,702,353.72. The trade was a 1.56% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 3,000 shares of Gilead Sciences stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $140.96, for a total transaction of $422,880.00. Following the transaction, the insider directly owned 128,779 shares in the company, valued at $18,152,687.84. This trade represents a 2.28% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 63,000 shares of company stock valued at $9,238,250. 0.30% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in GILD. Strategic Investment Solutions Inc. IL acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at $25,000. Vermillion & White Wealth Management Group LLC lifted its stake in Gilead Sciences by 71.4% during the 4th quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 85 shares in the last quarter. Corundum Trust Company INC acquired a new position in Gilead Sciences during the 3rd quarter worth about $26,000. Quattro Advisors LLC acquired a new position in Gilead Sciences in the 4th quarter valued at about $26,000. Finally, Wealth Preservation Advisors LLC grew its position in Gilead Sciences by 60.0% in the 4th quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 81 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.